RBC Capital analyst Simos Simeonidis cut his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $5.00 (from $7.00) following an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE